By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: every major GLP-1 weight-loss medication uses the same basic BMI threshold — 30 or higher on its own, or 27 or higher with a qualifying health condition — but there's more nuance underneath that headline number, including specific contraindications, special-population considerations, and situations where these medications are specifically not recommended, regardless of BMI.
If you've seen the "BMI ≥30, or ≥27 with a comorbidity" rule mentioned before, this goes deeper into what actually sits behind it — which conditions qualify, who's specifically excluded, and what professional medical guidelines say about candidacy beyond the basic number.
It's worth knowing upfront that this isn't a threshold that varies drug-by-drug — every FDA-approved chronic weight-management medication in this class uses essentially the same criteria:
All four list a similar set of qualifying comorbidities: high blood pressure, type 2 diabetes, high cholesterol (dyslipidemia), obstructive sleep apnea, and cardiovascular disease. In practical terms, this means the "which drug should I look into" decision and the "do I qualify at all" decision are largely separate questions — the eligibility bar itself is consistent across the class.
Beyond the BMI threshold, there's a set of absolute contraindications that apply across every medication in this class, regardless of BMI or how many comorbidities someone has.
Every medication covered here carries the same boxed warning and the same resulting contraindications:
These aren't cautions to weigh against benefits — they're absolute contraindications based on findings in animal studies, and a properly run intake process should be screening for this family history specifically, not just asking generally about thyroid problems.
All four medications carry warnings about acute pancreatitis, and labeling advises stopping the medication if pancreatitis is suspected during treatment. A prior history of pancreatitis is a specific area requiring caution and closer evaluation before starting.
None of these medications are recommended during pregnancy, and labeling for each specifies that treatment should be discontinued once pregnancy is recognized. This isn't specific to any one drug's safety data — it reflects a broader principle that intentional weight-loss therapy generally isn't appropriate during pregnancy, since weight loss itself offers no benefit to a pregnant patient and could carry risk to the fetus.
Because these medications slow down stomach emptying, they can affect how well other oral medications are absorbed — something worth flagging specifically if you're on any medication with a narrow safety margin, such as certain blood thinners or seizure medications, so your prescriber can monitor accordingly. For tirzepatide specifically, there's an increased risk of low blood sugar when combined with insulin or certain other diabetes medications, which may require your prescriber to adjust those other medications' doses.
This is the part that often gets left out of simplified eligibility checklists, and it matters. Meeting the BMI threshold doesn't automatically make someone a good candidate. Medical guidance points to several additional situations where these medications are considered inappropriate or where a different approach entirely is recommended:
Active eating disorders. For individuals with an active eating disorder — including anorexia nervosa, bulimia, or binge-eating disorder — appetite-suppressing medication is generally considered inappropriate and potentially harmful, since it can interact badly with existing disordered eating patterns. Clinical guidance in this area consistently points toward specialized eating disorder treatment instead, not toward weight-loss pharmacotherapy. A responsible intake process should be screening for this, not simply working from a BMI number in isolation.
Unrealistic expectations or unwillingness to engage long-term. Guidance also points to a mismatch in expectations as a reason these medications may not be the right fit — for instance, seeking purely cosmetic weight loss without a qualifying health indication, or expecting the medication to fully substitute for any lifestyle changes at all. Obesity medicine specialists generally look for candidates who understand that this is a long-term treatment approach requiring ongoing monitoring, not a short intervention.
There's no specific age-based contraindication in the FDA labeling for any of these medications. That said, clinical guidance flags older adults as a group where extra attention to muscle mass, strength, fall risk, and nutrition is particularly important during treatment, given research showing accelerated lean tissue loss in this population without deliberate mitigation. This doesn't disqualify older adults from treatment — it just means the conversation with a prescriber should include this consideration specifically.
Professional guidelines from endocrine and diabetes associations specifically recommend GLP-1 medications — and note tirzepatide and semaglutide as particularly strong options — for people managing both type 2 diabetes and obesity, given their combined benefit on blood sugar, weight, and cardiovascular risk. For diabetes-focused indications specifically (rather than the weight-management indication), BMI requirements can be less rigid than the strict obesity-drug criteria, since blood sugar control is being weighed alongside weight.
Two medications in this group currently have pediatric approval: Wegovy and Saxenda, both approved for adolescents 12 and older with obesity, defined using a BMI percentile standard for age and sex rather than the adult BMI cutoffs. Zepbound and Foundayo do not currently have pediatric obesity approvals, and off-label use in adolescents outside of a specialist setting is generally discouraged.
Beyond the FDA's baseline approval criteria, professional medical organizations have published their own guidance on when these medications should actually be recommended in practice. The consistent themes across guidance from diabetes and endocrine associations, as well as obesity medicine organizations, include:
If you're evaluating whether you're likely to qualify, the BMI/comorbidity threshold is the right starting point, but it isn't the whole picture. A responsible intake process — telehealth or in-person — should be asking about your full health history, not just calculating a number. If you have any of the specific contraindications above, or a history of disordered eating, that's important information to share directly and early, since it may change what kind of care is actually appropriate for you.
Q: Do all GLP-1 medications use the exact same BMI cutoffs?
Yes — Wegovy, Zepbound, Foundayo, and Saxenda all use the same basic threshold: BMI ≥30 on its own, or ≥27 with a qualifying weight-related health condition.
Q: I have a family history of thyroid cancer — does that automatically disqualify me?
It depends on the specific type. A personal or family history of medullary thyroid carcinoma specifically, or Multiple Endocrine Neoplasia syndrome type 2, is an absolute contraindication for every medication in this class. Other types of thyroid cancer aren't automatically disqualifying, but this is exactly the kind of history to discuss directly and specifically with a prescriber.
Q: Can I get one of these medications if I only want to lose a small amount of weight for appearance reasons?
If your BMI doesn't meet the threshold, or you don't have a qualifying health condition, these medications fall outside their approved use, and a responsible provider generally shouldn't prescribe them for that purpose.
Q: Are these medications safe for someone with a history of an eating disorder?
This is a genuinely important question to raise directly and honestly with any prescriber. Active eating disorders are generally considered a reason these medications are not appropriate, and specialized eating disorder treatment is the recommended path instead. If you have a history of disordered eating, even if not currently active, this is worth disclosing so it can be properly considered.
Q: Are teenagers eligible for these medications?
Only two — Wegovy and Saxenda — currently have FDA approval for adolescents 12 and older with obesity, using an age-and-sex-specific BMI percentile standard.
See also: How to Get Prescribed a GLP-1 Medication for the full evaluation and prescription process, and Do You Need Labs Before Starting? for what baseline bloodwork is recommended and why it matters.
If you or someone you know is struggling with an eating disorder, support is available. The National Alliance for Eating Disorders helpline can help connect you with resources and specialized care.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizWhat it actually takes to get prescribed Wegovy, Zepbound, or another GLP-1 medication — eligibility criteria, the evaluation process, insurance steps, and realistic timelines.
GLP-1 medications explained in plain language: what they are, how they work in your gut and brain, and what the research shows about weight loss results.
A clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.